Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
As various members of the drug supply chain blame one another for rising prescription drug costs, they're all making a lot of money off of said drugs.
The state of play: Between 2012 and 2016, net spending on drugs sold in pharmacies rose from $250.7 billion to $341 billion, according to a new Pew analysis.
- Pharmacy revenue more than doubled, and the profits of pharmacy benefit managers and drug manufacturers also increased.
While it's true that patients' discounts increased, that didn't stunt the growth in what people pay for drugs, mostly via premiums.
- PBMs passed a greater share of their rebates on to their customers, but growth in the size of the overall pie meant that their profits held steady all the while. And other revenue streams skyrocketed at the same time.
- Meanwhile, manufacturers significantly increased the value of patient discounts, but net sales still increased.
The bottom line: All of these profit increases are eventually borne by all of us through premiums, taxes and out-of-pocket costs.